| abstract |
Methods are provided for determining or otherwise evaluating a patient's response to treatment, particularly cancer treatment. The method includes analysis of the sample for the presence or absence of other biomarkers, such as HER3 markers or HER2 markers alone. In certain instances, the expected time to progression can be determined by first determining the HER2 positive patient and then further stratifying by using the presence or absence of a second biomarker (eg, HER3 marker). In addition, the data can be used to track the patient's response to the treatment regimen to assess the expected success of treating the patient with a specific regimen, to determine the effectiveness of the treatment regimen, or for clinical trials. Patients can be classified to create a uniform group. |